What Dr. Conway's Private Bets Say About His Skin in the Game at Optum

The smart money is rarely silent. When a CEO makes a major personal investment, it's a signal worth decoding. Dr. Patrick Conway, the newly minted CEO of Optum, has just placed a $130 million private bet on a digital health startup called Duos. The catch? Duos is led by an ex-Optum executive, and Conway's own public role is one of scaling back from unaligned provider contracts.

This creates a clear tension. On one hand, Conway is publicly championing a strategic pivot at Optum. Just last month, he told investors that the company is leaving some markets and ending contracts with medical care providers that aren't aligned with its integrated, value-based care model. The goal is to focus on markets where incentives are properly aligned to improve outcomes and reduce costs. On the other hand, his $130 million side bet is a massive vote of confidence in a digital health model that likely operates outside the traditional, vertically integrated Optum network he is now trying to refine.

His background adds another layer. Before joining Optum, Conway led the CMS Innovation Center, a government unit focused on testing new payment and delivery models. That experience points directly to his stated strategic focus on value-based care. The Duos investment, therefore, looks like a personal alignment with innovation in that same space. It's a bet on the future he wants Optum to embrace, but from the outside.

. The bottom line is one of skin in the game. Conway is using his own capital to back a vision he publicly endorses. Yet the scale of his private investment-$130 million-stands in stark contrast to the public challenges Optum faces, including a recent earnings miss and a major restructuring charge. For now, his move signals conviction in digital health innovation. But it also raises a question: if he's so bullish on this future, why is he simultaneously pulling back on the legacy provider model he's supposed to be transforming?

The Public Reality: A Division in Turnaround

The public numbers tell a story of a company under severe pressure. UnitedHealth's overall profit fell to $12.1 billion in 2025, its lowest since 2018. That drop is a direct result of a double whammy: soaring medical costs and lower reimbursements, especially in its core Medicare Advantage business. The strain is hitting Optum Health, the medical care arm Conway now leads, with brutal force. The unit operated at a loss of $278 million in 2025, a catastrophic reversal from the $7.8 billion gain it posted the prior year.

This isn't a minor stumble. It's a full-blown turnaround. Optum Health's full-year revenue was down 3% last year, marking the first contraction in decades for the broader UnitedHealth group. The culprit is clear: a combination of higher patient utilization and a new Medicare coding system, V28, that has slashed payments to insurers and value-based care companies by an estimated $130 billion. The pressure is intensifying, with the Trump administration's latest Medicare Advantage rate proposal for 2027 described as "disappointing" and threatening to force benefit cuts and market exits.

Conway's public strategy is a direct response to this crisis. He's leaving some markets and ending contracts with medical care providers that aren't aligned with Optum's integrated, value-based model. The goal is to focus on areas where incentives are properly aligned to improve outcomes and reduce costs. He's also cutting his affiliated network by nearly 20% and pushing providers toward better technology. This is a classic "back to basics" pivot, aimed at restoring profitability by shedding unproductive assets and contracts.

The bottom line is that Conway's $130 million private bet on Duos looks like a high-stakes personal wager on the future he's trying to build. While he's publicly scaling back the legacy provider model he's supposed to transform, he's using his own capital to back a digital health innovation that likely operates outside that traditional network. It's a bet on the strategic direction he wants Optum to go, but from the outside. The financial reality he must address is one of a division in deep trouble, and his skin in the game is a powerful signal of conviction in the solution he's championing.

Smart Money vs. The Street: What to Watch

The market's verdict is clear. After UnitedHealth's latest earnings, the stock fell 16% in premarket trading. That's a massive drop, signaling deep skepticism from the Street. For Conway's private bets to matter, they need to be backed by a shift in institutional sentiment. The first thing to watch is whether smart money starts accumulating UnitedHealth shares in the weeks ahead. A sustained 13F filing showing institutional buying would be a powerful counter-narrative to the panic selling. Conversely, continued selling would confirm that the smart money sees the underlying financial pressure at Optum as too severe to ignore, regardless of Conway's personal conviction.

On the ground, execution is the only thing that will move the needle. Conway's public strategy hinges on two operational levers: leaving some markets and ending contracts with medical care providers that aren't aligned with his value-based care model, and standardizing the electronic medical records (EMR) systems across the network. These are not just announcements; they are costly, complex projects. The key is to monitor for tangible progress. Are provider network cuts happening on schedule? Is the EMR standardization rollout gaining steam? These are the proxies for whether the turnaround plan is working or just talk.

The ultimate catalyst, however, is financial. The entire setup rests on whether value-based care initiatives can reverse Optum's brutal financial trends. The unit operated at a loss of $278 million in 2025, a catastrophic drop from a $7.8 billion gain the year before. Conway's $130 million bet on Duos is a high-stakes wager that this model can work. The market will judge that bet not on its promise, but on results. If Optum can show a path to regaining profitability-driven by lower costs and better outcomes from its aligned providers-then Conway's private accumulation of skin in the game will look like a brilliant leading indicator. If the losses persist, his side bet will look like a distraction from a failing core business. The numbers on the bottom line will tell the real story.